The Philadelphia Inquirer - 2006 Whole Article . Sanofi-Aventis SA's new treatment, Acomplia, also known as rimonabant , has shown promise in a half-dozen clinical trials in curbing the cravings that make people hungry. 费城询问者-2 006年整篇文章。 商 S anofi- A ventisS A的新治疗方法， a complia，也称为利 莫那班， 已表现出的承诺，在半打以上的临床试验在遏制的渴望，使人民挨饿。
Acomplia | Rimonabant: Weight Loss and Quit Smoking Help acomplia |利莫那班： 减肥和戒烟帮助
The experimental drug, which works differently from other weight loss medicines, could be approved by the Food and Drug Administration as soon as March, 2006. 该实验性药物，其中工程不同于其他减肥药品，可通过美国食品和药物管理局尽快于2006年3月。 And industry analysts predict it could become the world's first blockbuster antiobesity ( Weight Loss ) treatment, with annual sales of 2 billion to 4 billion euros, or $2.4 billion to $4.8 billion. EPH200 Diet Pill 工业分析家预测，它可能成为世界上第一个重磅炸弹antiobesity （ 体重减轻 ）治疗，年销售额20亿至40亿欧元，或24亿美元至48亿美元。 eph200饮食丸
If Acomplia gets marketing approval from the FDA later this month, Paris-based Sanofi-Aventis has said it could begin selling the Rimonabant pill by June 30 - 2006. 如果acomplia获得营销批准从美国FDA在本月稍后时间，总部设在巴黎的商Sanofi - Aventis曾表示可能开始出售 利莫那班 丸6月30日-2 006年。
What is Acomplia (rimonabant)? 什么是acomplia （利莫那班） ？
A single pill has been found to stop food cravings enough to help people lose weight , and could also help curb other unhealthy urges. 一个单一的丸已发现阻止食物的渴望，足以帮助人们减肥 ，还可以帮助遏制其他不健康的敦促。 Named Acomplia the drug in one study helped people who were overweight drop an average of 20 pounds - a significant weight loss . 命名acomplia药物在一项研究中帮助人们谁超重下降，平均二十〇磅-一个显着的体重减轻。 Acomplia contains the active ingredient Rimonabant. acomplia包含的活性成分利莫那班。
How does Acomplia (rimonabant) work? 如何acomplia （利莫那班）的工作呢？
Rimonabant (which will be brought to market as Acomplia) works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure. 利莫那班 （将被绳之以法，以市场为acomplia ）工程通过阻断cb1受体，其中2受体的发现，在一个新的生理系统所描述的所谓endocannabinoid系统（教统会系统） ，相信发挥关键作用，在规管食物摄入量和能源开支。
Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md. 研究人员想知道是否药物停止这一行动可能会抑制食欲，并于2001年，首次动物进行了研究，在国家研究所的酒精滥用和酗酒在贝塞斯达，马里兰州
In the study, genetically altered mice that lacked cannabinoid receptors ate less than their litter mates, even after 18 hours of fasting. 在这项研究中，基因改造的小鼠缺乏大麻素受体吃不到他们的垃圾交配，即使经过18小时的禁食。 When the normal mice were given rimonabant , which blocked their CB1 receptors, the mice reduced their food intake. 当正常小鼠给予利莫那班 ，阻止他们cb1受体，小鼠减少其食物摄入量。 In 2002, Sanofi-Synthelabo began human testing. 在2002年，赛诺菲-合成开始人体试验。
Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or other cravings more manageable. acomplia工程的针对性和选择性阻断cb1受体，帮助正常化过度活化，教统会制度和决策饥饿或其他的渴望，更便于管理。
This blocking of signals that control cravings appears to result in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and appears to reduce tobacco dependence without post cessation weight gain in people who smoke. 这阻断信号控制的渴望，似乎会导致体重减轻，改善心血管/代谢危险因素在超重/肥胖患者，而且看来，以减少烟草依赖，没有停止后体重增加的人谁吸烟。
Side Effects of Acomplia (rimonabant)? 副作用acomplia （利莫那班） ？
Acomplia was said to be well tolerated in early tests. acomplia据说是很好的耐受性，在早期的考验。 The only relatively common side effects were mild GI side effects and dizziness, and these were said to be transient. 唯一比较常见的副作用是轻度胃肠副作用和头晕，这些都是说是短暂的。